{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Squamous+Tumors&page=26",
    "query": {
      "condition": "Advanced Squamous Tumors",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 954,
    "total_pages": 96,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Squamous+Tumors&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Squamous+Tumors&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T23:58:41.959Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06171750",
      "title": "Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Cutaneous Tumor",
        "Subcutaneous Tumor",
        "Malignant Solid Tumor",
        "Solid Tumor",
        "Metastatic Solid Tumor",
        "Metastasis to Soft Tissue",
        "Non Small Cell Lung Cancer",
        "Cutaneous Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "tolododekin alfa",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ankyra Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2024-01-19",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 4,
      "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06171750"
    },
    {
      "nct_id": "NCT02560298",
      "title": "Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Basaloid Carcinoma",
        "Anal Canal Cloacogenic Carcinoma",
        "Anal Squamous Cell Carcinoma",
        "Metastatic Anal Canal Carcinoma",
        "Recurrent Anal Canal Carcinoma",
        "Stage IIIB Anal Canal Cancer",
        "Stage IV Anal Canal Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2016-08-23",
      "completion_date": "2023-08",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02560298"
    },
    {
      "nct_id": "NCT01884285",
      "title": "AZD8186 First Time In Patient Ascending Dose Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Castrate-resistant Prostate Cancer CRPC",
        "Squamous Non-Small Cell Lung Cancer sqNSCLC",
        "Triple Negative Breast Cancer TNBC"
      ],
      "interventions": [
        {
          "name": "Part A: AZD8186 monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Part B: AZD8186 monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Part C1: Abiraterone acetate combination with AZD8186",
          "type": "DRUG"
        },
        {
          "name": "Part D1: AZD2014 combination with AZD8186",
          "type": "DRUG"
        },
        {
          "name": "Part D2 AZD2014 combination with AZD8186",
          "type": "DRUG"
        },
        {
          "name": "Part C2: Abiraterone acetate combination with AZD8186",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 147,
      "start_date": "2013-07-09",
      "completion_date": "2020-02-07",
      "has_results": false,
      "last_update_posted_date": "2020-05-29",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01884285"
    },
    {
      "nct_id": "NCT01831089",
      "title": "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Gynecological Cancer",
        "Head and Neck Carcinoma",
        "Non-small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Non-squamous Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "PM01183 + paclitaxel +/- bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PharmaMar",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2013-09",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2020-04-10",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01831089"
    },
    {
      "nct_id": "NCT04619797",
      "title": "A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 542,
      "start_date": "2020-12-15",
      "completion_date": "2025-11-20",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04619797"
    },
    {
      "nct_id": "NCT00566540",
      "title": "Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Triple endoscopy and biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2007-12-11",
      "completion_date": "2010-02-25",
      "has_results": true,
      "last_update_posted_date": "2021-11-26",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00566540"
    },
    {
      "nct_id": "NCT03765918",
      "title": "Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab 200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiotherapy 60 Gray",
          "type": "RADIATION"
        },
        {
          "name": "Radiotherapy 66 Gray",
          "type": "RADIATION"
        },
        {
          "name": "Radiotherapy 70 Gray",
          "type": "RADIATION"
        },
        {
          "name": "Cisplatin 100 mg/m^2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 714,
      "start_date": "2018-12-17",
      "completion_date": "2026-11-17",
      "has_results": true,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 68,
      "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03765918"
    },
    {
      "nct_id": "NCT03177291",
      "title": "Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Non Small Cell Lung Cancer",
        "Advanced Cancer",
        "Metastatic Lung Cancer",
        "Squamous Cell Lung Cancer",
        "Non-Squamous Non-Small Cell Neoplasm of Lung"
      ],
      "interventions": [
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2017-09-26",
      "completion_date": "2024-12-04",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03177291"
    },
    {
      "nct_id": "NCT05904496",
      "title": "A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BGB-30813",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeiGene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2023-07-19",
      "completion_date": "2025-08-20",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 3,
      "location_summary": "Hackensack, New Jersey • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05904496"
    },
    {
      "nct_id": "NCT00975182",
      "title": "A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers"
      ],
      "interventions": [
        {
          "name": "GDC-0941",
          "type": "DRUG"
        },
        {
          "name": "erlotinib HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2009-09",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-15T23:58:41.959Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00975182"
    }
  ]
}